Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

High-profile investor Cathie Wood saw the record selloff in Moderna Inc.'s stock as an opportunity to bulk up her bets on the biotechnology company.

Cathie Wood's Ark ETFs buy a bunch of Moderna stock after record selloff

Freeport-McMoRan

Northern Trust

It may be earnings season for the S&P 500 — but revenue is on top of many investors' minds.

7 Stocks' Revenue Totally Smashes All Expectations

Medtronic

Tempus AI Inc

AI healthcare stocks can potentially revolutionize patient care as we know it. The groundbreaking technology is expected to have a pervasive impact on the investment world, with its most profound anticipated transformations in healthcare.

3 AI-Powered Healthcare Stocks Transforming Medicine

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

Major U.S. equities indexes moved lower on the first day of August as a pair of reports elevated concerns about the trajectory of the U.S. economy.

S&P 500 Gains and Losses Today: Moderna Drops as Soft Vaccine Demand Prompts Guidance Cut

U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday.

Crude Oil Moves Lower; Moderna Shares Plunge

Moderna, Inc.  MRNA shares are getting hit because of a bad earnings report. The Street didn't like the numbers.

Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report

Moderna Inc. (NASDAQ:MRNA ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Michael Yee - Jefferies Elliott Bosco - UBS Gena Wang - Barclays Luca Issi - RBC Capital Alexandria Hammond - Bank of America Edward Tenthoff - Piper Sandler Jessica Fye - JP Morgan Evan Wang - Guggenheim Greg - TD Securities Adi - Evercore ISI Operator Good day and thank you for standing by. Welcome to the Moderna second quarter 2024 conference call.

Moderna (MRNA) Q2 2024 Earnings Call Transcript

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plummeted almost 20% after the vaccine maker slashed its full-year sales forecast for respiratory vaccines by up to $1 billion. It now expects product sales for its respiratory franchise, which includes COVID-19 and respiratory syncytial virus (RSV) vaccines, to be between $3 billion to $3.5 billion, compared to its earlier projection of $4 billion.

Moderna shares dive on slashed 2024 sales forecast

Moderna (MRNA) shares plunged after the COVID-19 vaccine maker slashed its outlook on lower demand in Europe and a tough market in the U.S.

Moderna's Revenue Warning Sends the Stock Into the Red for 2024

Moderna Inc (NASDAQ:MRNA) stock is freefalling this morning, last seen down 15.2% to trade at $95.48 and pacing for its worst day since November 2021 after the company's second-quarter financial results.

Moderna Stock Gaps Lower After Earnings

Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago.

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

Moderna cut its outlook early Thursday despite delivering nearly double strong quarterly sales. Moderna stock tumbled.

Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat

Moderna Inc.'s stock MRNA tumbled 12% premarket Thursday, after the biotech cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter loss and revenue that topped estimates. Moderna had a net loss of $1.3 billion, or $3.33 a share, for the quarter, after a loss of $1.4 billion, or $3.62 a share, in the year-earlier period.

Moderna's stock slides 12% after it lowers full year sales guidance

Moderna reported second-quarter revenue that beat estimates and a narrower than-expected loss for the period. But the company slashed its full-year sales guidance, citing lower sales in Europe, a "competitive environment" for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025.

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market

Moderna slashed its 2024 forecast for sales of its COVID-19 and respiratory syncytial virus vaccines by up to 25%, or $1 billion, on Thursday as it expects very low sales to the EU this year.

Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue

Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024. "During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs.

Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

Biogen

GlaxoSmithKline

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Moderna will announce Q2 2024 earnings this Thursday, 1st August. Moderna stock hit highs of $450 per share in late 2021, but has since seen a decrease ~$120, and a current market cap valuation of ~$47bn. Revenue guidance for 2024 is for $4bn, although this is primarily dependent on the emergence of a significant private COVID-19 vaccination market, which is not guaranteed.

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

WOBURN, Mass.--(BUSINESS WIRE)-- #leveragen--Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered a multi-target research, option and license agreement with Moderna, Inc. Under the agreement, Leveragen will employ its proprietary fully human single domain antibody discovery platform to generate a panel of optimized binding modules against therapeutic targets selected by Moderna. Moderna will have the.

Leveragen Announces Collaboration Agreement with Moderna Using Proprietary Fully Human Single Domain Antibody Technology to Advance Therapeutics

Axsome Therapeutics

Halozyme Therapeutics

Krystal Biotech

Sarepta Therapeutics

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

5 Biotech Stocks to Bet On Bright Industry Prospects

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS

Ardelyx

Cassava Sciences Inc

Biotech stocks are known for their high volatility and potential for massive gains. The success in the sector often hinges on progressive and often groundbreaking medical advancements.

Get Your Money Out of These 3 Biotech Stocks Before the End of July

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

News for Moderna Stock (MRNA)